USANA Health Sciences, Inc. (NYSE:USNA) Given Average Rating of “Buy” by Analysts

Shares of USANA Health Sciences, Inc. (NYSE:USNA) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $73.67.

Several brokerages have commented on USNA. Jefferies Financial Group initiated coverage on USANA Health Sciences in a research note on Thursday, August 22nd. They set a “hold” rating and a $65.00 target price on the stock. ValuEngine upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price target on the stock in a report on Saturday, October 26th.

In other USANA Health Sciences news, Director Robert Auciaux sold 4,018 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Walter Noot sold 1,176 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $75.98, for a total transaction of $89,352.48. Following the sale, the chief operating officer now owns 1,444 shares of the company’s stock, valued at $109,715.12. The disclosure for this sale can be found here. Insiders have sold a total of 8,385 shares of company stock worth $617,279 in the last 90 days. Company insiders own 42.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in USNA. Massachusetts Financial Services Co. MA grew its holdings in shares of USANA Health Sciences by 12.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,801 shares of the company’s stock worth $465,000 after acquiring an additional 759 shares during the period. State of Alaska Department of Revenue grew its stake in shares of USANA Health Sciences by 119.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 9,917 shares of the company’s stock valued at $678,000 after purchasing an additional 5,392 shares during the period. Texas Permanent School Fund grew its stake in shares of USANA Health Sciences by 190.7% during the 3rd quarter. Texas Permanent School Fund now owns 8,786 shares of the company’s stock valued at $601,000 after purchasing an additional 5,764 shares during the period. Point72 Asset Management L.P. grew its stake in shares of USANA Health Sciences by 6,579.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 13,358 shares of the company’s stock valued at $914,000 after purchasing an additional 13,158 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of USANA Health Sciences by 27.3% during the 2nd quarter. Janus Henderson Group PLC now owns 9,074 shares of the company’s stock valued at $721,000 after purchasing an additional 1,947 shares during the last quarter. 52.87% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:USNA traded up $1.85 during trading on Friday, reaching $76.32. 102,627 shares of the stock traded hands, compared to its average volume of 229,211. The stock has a market cap of $1.59 billion, a P/E ratio of 14.79 and a beta of 0.30. The stock has a 50-day moving average of $73.55 and a two-hundred day moving average of $70.28. USANA Health Sciences has a 52-week low of $58.30 and a 52-week high of $125.61.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.22. The company had revenue of $260.60 million during the quarter, compared to analyst estimates of $256.22 million. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The firm’s revenue for the quarter was down 12.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 EPS. Analysts predict that USANA Health Sciences will post 3.99 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Featured Story: How to Trade Using Analysts Ratings

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit